Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 3 | 3 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Oral Drug Delivery Market - Introduction | 6 | 1 |
| GBI Research Report Guidance | 6 | 1 |
| Oral Drug Delivery Market - Overview | 7 | 9 |
| Introduction to Oral Drug Delivery | 7 | 1 |
| Advantages of Oral Drug Delivery in the Pharmaceutical Market | 7 | 1 |
| Patent Extension and Protection from Generic Competition | 8 | 1 |
| Reformulation of Existing Products | 8 | 1 |
| Optimizing Returns on R&D Investment | 8 | 1 |
| Improving Underperforming Products - Compliance, Bioavailability and Safety Benefits | 9 | 1 |
| Role of Drug Delivery in Repositioning of Existing Drugs by Reformulations | 10 | 1 |
| Hierarchy of Reformulation | 10 | 1 |
| FDA Approval of Drugs by Type | 11 | 1 |
| Patent Expiries and their Effect on the Pharmaceutical Industry | 12 | 1 |
| Patent Expirations of Major Drugs will Lead to a Decline in the Revenue Generated by Big Pharma | 13 | 1 |
| Repositioning of Existing Drugs through Reformulations is a Lifecycle Management Strategy | 14 | 1 |
| Repositioning of Marketed Drugs | 14 | 1 |
| Oral Drug Delivery Market Forecast | 15 | 1 |
| Oral Drug Delivery Market - Marketed Oral Products by Indication | 16 | 3 |
| Marketed Oral Small Molecules by Therapy Area | 16 | 1 |
| Marketed Oral Peptides by Indication | 17 | 1 |
| Marketed Oral Proteins by Indication | 18 | 1 |
| Oral Drug Delivery Market - Pipeline Analysis | 19 | 4 |
| Oral Small Molecules Pipeline by Phase | 19 | 1 |
| Oral Peptide Pipeline by Phase | 20 | 1 |
| Oral Proteins Pipeline by Phase | 21 | 1 |
| Oral Vaccines Pipeline by Phase | 22 | 1 |
| Oral Drug Delivery Market - Technology Landscape | 23 | 10 |
| Orally Disintegrating Tablets | 23 | 1 |
| Key Patented Technologies for Formulating ODTs | 23 | 1 |
| Zydis Technology | 23 | 1 |
| Orasolv Technology | 23 | 1 |
| Durasolv Technology | 23 | 1 |
| WowTab Technology | 23 | 1 |
| Cotton Candy Technology | 23 | 1 |
| Oraquick Technology | 23 | 1 |
| NanoCystal Technology | 23 | 1 |
| Shearform Technology | 23 | 1 |
| Pharmaburst Technology | 24 | 1 |
| Frosta Technology | 24 | 1 |
| Technologies Used in Oral Delivery of Peptides and Proteins | 24 | 1 |
| Chemical Modification | 24 | 1 |
| Case 1: Enhanced Membrane Permeation through Chemical Modifications of Proteins and Peptides | 24 | 1 |
| Case 2: Reestablishment of Normal Glucose Control in Diabetic Patients Using Chemical Modifications to Proteins and Peptides | 24 | 1 |
| Enzyme Inhibitors | 25 | 1 |
| Case 1: Increase in the Intestinal Insulin Absorption Using Enzyme Inhibitors | 25 | 1 |
| Case 2: Study of Use of Thiomers as Enzyme Inhibitors and Manipulation of pH to Deactivate Enzymes | 25 | 1 |
| Absorption Enhancement | 25 | 1 |
| Case 1: Increased Intestinal Absorption of Insulin and Chemotherapeutic Agents Using Zonula Occludens Toxin | 25 | 1 |
| Case 2: Absorption Enhancement of Peptide Drugs Using Chitosans | 26 | 1 |
| Using Mucoadhesive Polymers | 26 | 1 |
| Case 1: Use of Gastrointestinal Mucoadhesive Patch System to Enhance Absorption and Site Specific Drug Delivery of Proteins | 26 | 1 |
| Case 2: Inhibition of Luminal Degradation of Drugs and Enhanced Bioavailability of Orally Administered Proteins Using Polymers with Mucoadhesive Properties | 26 | 1 |
| Nanotechnology in Drug Delivery | 27 | 1 |
| Nano-Engineered Drugs | 27 | 1 |
| Nano Crystals | 27 | 1 |
| Nano Suspensions | 27 | 1 |
| Nano-Carriers | 28 | 1 |
| Carbon and Ceramic Nanostructures | 28 | 1 |
| Dendrimers | 28 | 1 |
| Liposomes | 28 | 1 |
| Micelles and Polymeric Nanoparticles | 28 | 1 |
| Applications of Nano-Enabled Drug Delivery | 29 | 1 |
| Gene and Vaccine Delivery | 29 | 1 |
| Controlled-Release Devices | 30 | 1 |
| Improved Drug Bioavailability and Solubility | 30 | 1 |
| Applied Diagnosis, Etiology, Prognosis and Therapy | 30 | 1 |
| Tissue Specific Delivery | 30 | 1 |
| Nanotechnology in Drug Delivery - Case Studies | 31 | 1 |
| Abraxis Bioscience, Inc. - Paclitaxel-Albumin Nanoparticles (Abraxane) | 31 | 1 |
| Nanospectra Biosciences - AuroShell Particles | 31 | 1 |
| Calando Pharmaceuticals, Inc. - RONDEL Technology | 31 | 1 |
| Elan Corporation - NanoCrystal Technology | 32 | 1 |
| The Oral Drug Delivery Market - Company Analysis, Key Pipeline Molecules, Proprietary Technologies and Deals Landscape | 33 | 32 |
| Emisphere Technologies Inc. | 33 | 1 |
| Key Pipeline Products of Emisphere Technologies | 33 | 1 |
| Oral Acyclovir | 34 | 1 |
| GLP-1/ NN9924 | 34 | 1 |
| G4544 (gallium nitrate) | 35 | 1 |
| Oral Heparin | 36 | 1 |
| Oral Insulin | 37 | 1 |
| Oral PYY (Peptide YY) | 38 | 1 |
| SMC021 (salmon calcitonin) | 39 | 1 |
| Proprietary Technology | 40 | 1 |
| Eligen Technology | 40 | 1 |
| Deals Landscape (2009-2011) | 41 | 1 |
| Emisphere Technologies Enters Into Licensing Agreement with Novo Nordisk in December 2010 | 41 | 1 |
| Emisphere Technologies Enters Into Research Collaboration with Alchemia in March 2010 | 41 | 1 |
| Emisphere Technologies Entered Into Co-Development Agreement with AAIPharma in April 2009 | 41 | 1 |
| Unigene Laboratories Inc. | 42 | 1 |
| Key Pipeline Products of Unigene Laboratories | 42 | 1 |
| OSTORA | 43 | 1 |
| Oral PTH | 44 | 1 |
| UGP-281 | 44 | 1 |
| Anti-Inflammatory Peptides | 45 | 1 |
| Proprietary Technology | 46 | 1 |
| Peptelligence | 46 | 1 |
| E. coli Expression System | 46 | 1 |
| Amidation Technology | 46 | 1 |
| Deals Landscape (2009-2011) | 47 | 1 |
| Unigene Laboratories Enters Into Joint Venture Agreement with Nordic Bioscience, October 2011 | 47 | 1 |
| Unigene Laboratories Enters Into Co-Development Agreement with GlaxoSmithKline, August 2011 | 47 | 1 |
| Unigene Amends Licensing Agreement with GlaxoSmithKline, December 2010 | 47 | 1 |
| Unigene Laboratories Enters Into Licensing Agreement with Tarsa Therapeutics, October 2009 | 47 | 1 |
| Aptalis | 48 | 1 |
| Key Pipeline Products of Aptalis | 48 | 1 |
| EUR-1008 (pancrelipase) | 48 | 1 |
| EUR-1025 (ondansetron hydrochloride) | 49 | 1 |
| Proprietary Technology | 49 | 1 |
| Taste Masking Technology | 50 | 1 |
| Bioavailability Enhancement Technology | 50 | 1 |
| Customized Drug Release Technology | 51 | 1 |
| Deals Landscape | 52 | 1 |
| Axcan Pharma Acquired Eurand N.V. in February 2011 | 52 | 1 |
| Axcan Pharma (now Aptalis) Acquires Mpex Pharmaceuticals for $223.6m in August 2011 | 52 | 1 |
| Pinnacle Biologics Acquires Photofrin and Photobarr from Axcan Pharma in March 2011 | 52 | 1 |
| Encap Drug Delivery | 53 | 1 |
| Proprietary Technology | 53 | 1 |
| DuoCap Delivery System | 53 | 1 |
| ENCODE | 53 | 1 |
| Abusolve Technology (Abuse Resistant Formulations) | 54 | 1 |
| Deals Landscape | 54 | 1 |
| Encap Drug Delivery Enters Into Co-Development Agreement with Lena Nanoceutics | 54 | 1 |
| Encap Drug Delivery Enters Into Co-Development Agreement with Probac in May 2009 | 54 | 1 |
| Ethypharm | 54 | 1 |
| Proprietary Technology | 54 | 1 |
| Multicaps | 54 | 1 |
| Locktab | 54 | 1 |
| Flashtab | 54 | 1 |
| Drugsol Technology | 54 | 1 |
| Deals Landscape | 55 | 1 |
| Lansen Pharmaceutical Enters into Co-Marketing Agreement with Ethypharm in October 2011 | 55 | 1 |
| Meda Expands Co-Marketing Agreement with Ethypharm in December 2009 | 55 | 1 |
| Archimedes Enters Into Co-Marketing Agreement with Ethypharm in April 2009 | 55 | 1 |
| Alkermes | 56 | 1 |
| Key Pipeline Products | 56 | 1 |
| ALKS 33 | 56 | 1 |
| ALKS 36 | 57 | 1 |
| Proprietary Technology | 57 | 1 |
| Oral Controlled Release (OCR) | 57 | 1 |
| Bioavailability Enhancement | 58 | 1 |
| Deals Landscape | 58 | 1 |
| Alkermes Completes Merger with Elan Drug Technologies in September 2011 | 58 | 1 |
| Civitas Therapeutics Acquires Pulmonary Patent Portfolio of Alkermes in December 2010 | 58 | 1 |
| Acceleron Pharma Enters into Licensing Agreement with Alkermes in December 2009 | 58 | 1 |
| HalcyGen Pharmaceuticals Limited | 59 | 1 |
| Key Pipeline Drugs | 59 | 1 |
| SUBACAP/SUBA itraconazole | 59 | 1 |
| Proprietary Technology | 60 | 1 |
| SUBA Technology | 60 | 1 |
| CleanTaste Technology | 60 | 1 |
| Deals Landscape | 60 | 1 |
| HalcyGen Acquires Mayne Pharma from Hospira in September 2009 | 60 | 1 |
| Aegis Therapeutics | 61 | 1 |
| Key Pipeline Drugs | 61 | 1 |
| AFPep (alpha fetoprotein peptide) | 61 | 1 |
| OB3 Peptide | 61 | 1 |
| Proprietary Technology | 62 | 1 |
| Intravail | 62 | 1 |
| Protek | 62 | 1 |
| SkyePharma | 62 | 1 |
| Key Pipeline Drugs | 62 | 1 |
| SKP-1052 | 62 | 1 |
| Proprietary Technology | 63 | 1 |
| GeoMatrix | 63 | 1 |
| Geoclock | 63 | 1 |
| Medicated Chewing Gum Technology | 63 | 1 |
| Flamel Technologies | 63 | 1 |
| Key Pipeline Products | 63 | 1 |
| Genvir (acyclovir) | 63 | 1 |
| Proprietary Technology | 64 | 1 |
| Micropump | 64 | 1 |
| LiquiTime | 64 | 1 |
| Trigger Lock | 64 | 1 |
| Medusa | 64 | 1 |
| Oral Drug Delivery Market - Appendix | 65 | 4 |
| Market Definitions | 65 | 1 |
| Abbreviations | 65 | 1 |
| Sources | 66 | 1 |
| Research Methodology | 67 | 2 |
| Coverage | 67 | 1 |
| Secondary Research | 67 | 1 |
| Primary Research | 68 | 1 |
| Expert Panel Validation | 68 | 1 |
| Contact Us | 68 | 1 |
| Disclaimer | 68 | 1 |
